Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of cTIV in Healthy Participants Aged 6 Months and Above
NCT07889193Phase 1Not yet recruiting
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Oct 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in seasonal influenza (3 arms), sponsored by Sinovac Biotech Ltd. Primary endpoint: Incidence of adverse reactions at 28 days. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
seasonal influenza
Beyond the preview
Go deeper on NCT07889193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07889193.